Abstract:SESSION TITLE: Lung Cancer III SESSION TYPE: Original Investigation Poster PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM PURPOSE: Limited data are available on treatment experience in patients with advanced lung adenocarcinoma with unknown EGFR gene status (UN-EGFR-GS). We studied the demographic profile and treatment outcomes of advanced NSCLC patients with adenocarcinoma, which the EGFR gene status was unknown. METHODS: Retrospective study of patients with UN-EGFR-GS advanced lung adenocarcinoma over a 5-year period at a tertiary care institute in China. Patients diagnosed with stage IIIB or IV were included for analysis during 2009 and 2013. And the efficacy of EGFR-TKIs in advanced NSCLC was evaluated in patients with UN-EGFR-GS. RESULTS: In total, 113 patients were included, 95.6% of whom had stage IV disease. Thirty six patients received gemcitabine plus platinum as the first-line treatment, 32 received pemetrexed plus platinum, 11 received EGFR-TKIs and the rest received docetaxel, paclitaxel, novelbine and etc. Forty four patients received oral EGFR-TKIs as the second-line treatment. At the end of follow-up (2015-3-30), 91 patients were dead and 22 patients were alive or lost follow up. The median survival of this whole cohort was 20.0m (95%CI, 16.1m-24.0m,). The overall survival was not associated with the chemotherapy drugs used in the first-line treatment. The patients (19.0m, 95%CI; 11.4m-26.5m) used pemetrexed plus platinum lived no longer than those who used other regimens (20.5m, 95%CI; 13.4m-27.4m) (p=0.272). In the gemcitabine plus platinum group, the median survival was 19.9m (95%CI; 9.2m-30.6m), which was not longer than other groups (20.0m, 95%CI; 15.4m-27.4m) (p=0.404). Those who had a chance to take EGFR-TKIs lived numerically longer than never; the median survival was 24.8m (19.1m-30.5m, 95%CI) and 16.3m (12.7m-19.9m, 95%CI), respectively. However, the overall difference was not significant (p=0.184). CONCLUSIONS: The median survival of patients with advanced lung adenocarcinoma with UN-EGFR-GS was 20m. Oral EGFR-TKIs appear to be useful for this group of patients. CLINICAL IMPLICATIONS: EGFR-TKIs showed to be the oppotunity for the advanced lung adenocarcinoma patients with UN-EGFR-GS. DISCLOSURE: The following authors have nothing to disclose: YuLong Zheng, Xin Xu, Cheng Xiao, ChengYu Mao, Jiong Qian, HaiPing Jiang, Jing Deng, Nong Xu No Product/Research Disclosure Information

EGFR-TKI Therapy Prolongs Survival in Non-small Cell Lung Cancer Patients with Brain Metastases or Bone Metastases

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Efficacy of EGFR-TKI Therapy in Patients with Brain Metastases from Non-Small-cell Lung Cancer: A Meta-Analysis

Epidermal Growth Factor Receptor (egfr)–tyrosine Kinase Inhibitors (tkis) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma

EGFR-Tyrosine Kinase Inhibitor Combined with Radiotherapy in 105 Patients of Lung Adenocarcinoma with Brain Metastasis: A Retrospective Study of Prognostic Factor Analysis

A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer

Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases

A real-world study in advanced non-small cell lung cancer with de novo brain metastasis

Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Superior Efficacy of Immunotherapy‐based Combinations over Monotherapy for EGFR‐mutant Non‐small Cell Lung Cancer Acquired Resistance to EGFR‐TKIs

Analysis of Prognostic Factors of Non-Small Cell Lung Carcinoma Patients with Bone Metastases Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

Clinical Experience on Treatment of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status from a Tertiary Care Center in China

Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

Outcomes of 27 Non-Small Cell Lung Cancer Patients Receiving Resections of Paired Primary Pulmonary and Brain Metastatic Tumours: Is EGFR Negative Mutation of Brain Metastasis Bring More Benefit?

TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases

The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs

Long-term Survival with Targeted Therapy in an Advanced Non-Small Cell Lung Cancer Patient Based on Genetic Profiling.